Clinical and Pathological Features of Myeloid Leukemia Cutis
Overview
Affiliations
Background: Myeloid leukemia cutis is the terminology used for cutaneous manifestations of myeloid leukemia.
Objective: The purpose of this study was to study the clinical, histopathological and immunohistochemical features of myeloid leukemia cutis.
Methods: This was a retrospective study of clinical and pathological features of 10 patients with myeloid leukemia cutis.
Results: One patient developed skin lesions before the onset of leukemia, seven patients developed skin infiltration within 4-72 months after the onset of leukemia, and two patients developed skin lesions and systemic leukemia simultaneously. Of these patients, five presented with generalized papules or nodules, and five with localized masses. The biopsy of skin lesions showed a large number of tumor cells within the dermis and subcutaneous fat layer. Immunohistochemical analysis showed strong reactivity to myeloperoxidase (MPO), CD15, CD43 and CD45 (LCA) in most cases. NPM1 (nucleophosmin I) and FLT3-ITD (Fms-like tyrosine kinase 3-internal tandem duplication) mutations were identified in one case. Five patients with acute myelogenous leukemia and one patient with chronic myelomonocytic leukemia died within two months to one year after the onset of skin lesions.
Study Limitations: This was a retrospective and small sample study.
Conclusions: In patients with myelogenous leukemia, skin infiltration usually occurs after, but occasionally before, the appearance of hemogram and myelogram abnormalities, and the presence of skin infiltration is often associated with a poor prognosis and short survival time. myeloid leukemia cutis often presents as generalized or localized nodules or masses with characteristic pathological and histochemical findings.
Bakshi N, Al Hejazi A, Al-Maghraby H, Al Mugairi A, Alotaibi A, Khogeer H Cancers (Basel). 2025; 17(2).
PMID: 39858003 PMC: 11763774. DOI: 10.3390/cancers17020221.
Organomegalies as a predictive indicator of leukemia cutis in patients with acute myeloid leukemia.
Kanitthamniyom C, Wannaphut C, Pattanaprichakul P, Kungwankiattichi S, Owattanapanich W PLoS One. 2024; 19(2):e0297805.
PMID: 38363781 PMC: 10871476. DOI: 10.1371/journal.pone.0297805.
Leukemia Cutis-The Current View on Pathogenesis, Diagnosis, and Treatment.
Robak E, Braun M, Robak T Cancers (Basel). 2023; 15(22).
PMID: 38001655 PMC: 10670312. DOI: 10.3390/cancers15225393.
Rare Presentation of Acute Myeloid Leukemia With TP53 Mutation and Dermatologic Manifestations.
Lott 3rd R, Stawitzky S, Stroia A, Awad A, Kam A, Bleicher M Cureus. 2023; 15(4):e37012.
PMID: 37139024 PMC: 10150939. DOI: 10.7759/cureus.37012.
Dermatological manifestations of hematologic neoplasms. Part I: secondary specific skin lesions.
de Souza P, Amorim R, Sousa L, Batista M An Bras Dermatol. 2022; 98(1):5-12.
PMID: 36344350 PMC: 9837649. DOI: 10.1016/j.abd.2022.06.002.